ProCE Banner Activity

How I Choose Second-line Treatment After Crizotinib Failure in Advanced NSCLC

Clinical Thought
Despite improving outcomes for patients with ALK-positive NSCLC, many patients will relapse on initial therapy with crizotinib. In this commentary, I review second-generation ALK inhibitors that are becoming available as second-line therapy and provide considerations for matching specific agents to patients.

Released: June 20, 2016

Expiration: June 19, 2017

No longer available for credit.

Share

Faculty

Tony Mok

Tony Mok, MD

Professor
Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Boehringer Ingelheim

Genentech BioOncology

Lilly

Novartis Oncology

Faculty Disclosure

Primary Author

Tony Mok, MD

Professor
Department of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong

Tony Mok, MD, has disclosed that he has received consulting fees from ACEA Biosciences, AstraZeneca, Aveo, Biodesix, BioMarin, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, GeneDecode, GlaxoSmithKline, Janssen, Merck Serono, MSD, Novartis, OncoGenex, Pfizer, Roche/Genentech, SFJ Pharmaceutical, and Vertex; fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, prIME Oncology, and Roche/Genentech; and funds for research support from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Clovis Oncology, MSD, Novartis, Pfizer, and Roche.